The RET mutation (KIF5B–RET fusion), which is found in 1%–2% of lung cancer patients and is also targetable by multiple treatment modalities, was discovered in one patient by liquid biopsy but missed by tissue biopsy. Here, KIF5B is linked to lung carcinoma.